To provide statements and recommendations based on the best available evidence, about the use of trastuzumab (Herceptin®) as adjuvant therapy for the treatment of patients with HER2-positive early breast cancer and for the treatment of patients with HER2-positive metastatic breast cancer. For information on the Pharmaceutical Benefits Scheme (PBS) listing for Herceptin® please see the PBS section in this guideline.
A clinical practice guideline developed by the National Breast Cancer Centre (NBCC)*
This document supplements guideline recommendations on systemic adjuvant therapy, contained in the NBCC* Clinical Practice Guidelines for the Management of Early Breast Cancer, 2nd edition, 2001; and guideline recommendations on the management of metastatic disease, contained in the NBCC* Clinical Practice Guidelines for the Management of Advanced Breast Cancer, 2nd edition, 2001.
Incorporates published evidence to November 2006
- The Faculty of Radiation Oncology - The Royal Australian and New Zealand College of Radiologists
- The Royal Australasian College of Physicians
- The Royal Australasian College of Surgeons
ISBN Print: 978-1-74127-016-7
ISBN Online: 978-1-74127-017-4
© Cancer Australia 2011
* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.
|Guideline Topic||Advanced Breast Cancer|
|Cancer Types||Breast cancer|
This resource was developed, reviewed or revised more than 5 years ago and may no longer reflect current evidence or best practice.